Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Real-World data unlock better breast cancer treatment sequences?

NCT ID NCT07743944

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is a large registry that will follow about 2,000 adults in China with a type of advanced breast cancer called HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null). The goal is to describe the patients' characteristics, genetic testing, treatment patterns, and outcomes across different lines of therapy. It will also track quality of life and healthcare costs. By observing what happens in everyday practice, researchers hope to understand which treatment approaches are most effective and how to improve care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
This registry could help identify which treatment sequences work best for HR+/HER2- metastatic breast cancer in real-world settings, potentially guiding more personalized and effective care.
What could go wrong
As an observational registry, it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability, and may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)

    RECRUITING

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.